RenovoRx, Inc. (RNXT) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US75989R1077

Price
1.49 USD
Market cap
67.24 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

RenovoRx, Inc. financials

Fiscal year2025
Revenue1.12 m USD
Gross profit796,000.00 USD
Operating income-12.51 m USD
EBIT-11.17 m USD
Net income-11.17 m USD
Diluted EPS – continuing operations-0.32 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.